Assess whether biosimilarity is analytically justified (933732)

Situation

A mid-size sponsor after a complete response letter cannot treat a competitor label that just got a narrower indication as color commentary on 505(b)(2) literature-to-product bridge table. 505(b)(2) development lead must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.
• 505(b)(2) literature-to-product bridge table is missing the fact 505(b)(2) development lead needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a competitor label that just got a narrower indication and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.